HemoGenyx Pharmaceuticals Plc (GB:HEMO)
LSE:HEMO
Top Page
HemoGenyx Pharmaceuticals Plc
(LSE:HEMO)
Select Model
Select Model
Rating:47Neutral
Price Target:
725.00 p
▲(27.64% Upside)
Action:UpgradedDate:01/28/26
The score is held down primarily by very weak financial performance (no revenue, ongoing losses and cash burn, and higher balance-sheet risk from lower equity and increased leverage). Technicals provide some offset with strong recent momentum, but overbought indicators add near-term risk, and valuation support is limited due to a negative P/E and no dividend yield.
Positive Factors
Specialized Therapeutic Focus
A clear, narrow focus on hematology and oncology and blood/immune disorders supports durable R&D prioritization and scientific expertise. This specialization can improve trial design, regulatory strategy, and partner interest, sustaining pipeline productivity over months.
Negative Factors
No Revenue
Absence of any revenue over multiple years signals a pre-revenue R&D stage with no commercial validation yet. This structurally raises execution risk, keeps profitability distant, and makes the company dependent on external financing or partnerships to sustain operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized Therapeutic Focus
A clear, narrow focus on hematology and oncology and blood/immune disorders supports durable R&D prioritization and scientific expertise. This specialization can improve trial design, regulatory strategy, and partner interest, sustaining pipeline productivity over months.
Read all positive factors
HemoGenyx Pharmaceuticals Plc (HEMO) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£61.43M
Dividend YieldN/A
Average Volume (3M)113.41K
Price to Earnings (P/E)―
Beta (1Y)0.26
Revenue GrowthN/A
EPS GrowthN/A
CountryUK
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.42
Shares Outstanding6,425,429
10 Day Avg. Volume30,447
30 Day Avg. Volume113,406
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)14.90
Price to Sales (P/S)0.00
P/FCF Ratio-3.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
HemoGenyx Pharmaceuticals Plc Business Overview & Revenue Model
Company Description
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoie...
How the Company Makes Money
null...
HemoGenyx Pharmaceuticals Plc Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
28
Negative
Cash Flow
32
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -631.38K | -639.28K | -645.68K | -2.60M | -283.65K | -350.72K |
| EBITDA | -6.94M | -4.71M | -5.73M | -3.42M | -2.39M | -1.96M |
| Net Income | -7.81M | -5.62M | -6.69M | -3.98M | -5.10M | -2.08M |
Balance Sheet | ||||||
| Total Assets | 3.10M | 4.21M | 6.11M | 7.09M | 8.52M | 2.66M |
| Cash, Cash Equivalents and Short-Term Investments | 226.73K | 159.26K | 1.25M | 2.53M | 6.84M | 1.81M |
| Total Debt | 2.20M | 2.62M | 2.95M | 3.42M | 10.15K | 1.63M |
| Total Liabilities | 3.65M | 3.36M | 3.32M | 3.85M | 352.84K | 1.79M |
| Stockholders Equity | -500.15K | 897.51K | 2.82M | 3.28M | 8.19M | 890.84K |
Cash Flow | ||||||
| Free Cash Flow | -5.58M | -4.13M | -6.22M | -3.34M | -3.45M | -1.97M |
| Operating Cash Flow | -5.57M | -4.12M | -6.11M | -2.91M | -2.63M | -1.80M |
| Investing Cash Flow | 235.15K | -24.90K | -31.94K | -420.25K | -938.95K | -169.68K |
| Financing Cash Flow | 1.91M | 3.08M | 4.45M | -110.14K | 8.78M | 3.21M |
HemoGenyx Pharmaceuticals Plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | £42.68M | -137.50 | 11.97% | 2.94% | 11.92% | -33.76% | |
56 Neutral | £24.54M | -1.64 | -197.54% | ― | 3.31% | 21.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | £30.32M | -1.92 | -53.86% | ― | ― | ― | |
47 Neutral | £61.43M | -0.27 | -3931.14% | ― | ― | ― | |
46 Neutral | £25.36M | -3.00 | 3817.30% | ― | ― | ― | |
40 Underperform | £18.29M | -6.19 | -213.66% | ― | 39.88% | 81.33% |
* Healthcare Sector Average
GB:HEMO
HemoGenyx Pharmaceuticals Plc
956.00
762.25
393.42%
GB:IMM
ImmuPharma
5.05
2.38
89.31%
GB:HVO
Open Orphan Plc
6.20
-6.26
-50.23%
GB:POLB
Poolbeg Pharma Ltd.
4.30
1.55
56.36%
GB:AREC
Arecor Therapeutics PLC
65.00
22.50
52.94%
GB:APTA
Aptamer Group Plc
0.63
0.37
140.38%
HemoGenyx Pharmaceuticals Plc Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
Hemogenyx Pharmaceuticals Updates Share Capital and Voting Rights Structure
Neutral
Feb 27, 2026
Hemogenyx Pharmaceuticals plc, a clinical-stage biopharmaceutical group listed on the LSE and focused on therapies for blood and autoimmune diseases, operates from London with U.S. subsidiaries in New York City supporting its pipeline of product c...
Private Placements and FinancingRegulatory Filings and Compliance
Hemogenyx Raises £118,632 Through Warrant Exercise and Expands Share Capital
Positive
Feb 23, 2026
Hemogenyx Pharmaceuticals has received notices to exercise warrants over 50,841 new ordinary shares at prices between 180p and 350p, raising £118,632 in fresh capital. The new shares will be admitted to the FCA’s Official List and to tr...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Hemogenyx Raises £2.5m to Advance CAR-T Trials in Adult and Pediatric AML
Positive
Feb 10, 2026
Hemogenyx Pharmaceuticals has raised £2.5 million from a consortium of private investors via a direct subscription for 333,333 new shares at £7.50 each, alongside three-year warrants exercisable at £9, increasing its issued share ca...
Business Operations and StrategyPrivate Placements and Financing
Hemogenyx Raises £2.5m to Advance AML CAR-T Trials and Reduce Costs
Positive
Feb 10, 2026
Hemogenyx Pharmaceuticals has raised £2.5 million through a direct subscription of 313,333 new shares at £7.50 each from a consortium of private investors, accompanied by three-year warrants exercisable at £9. The funds will primari...
Regulatory Filings and Compliance
Hemogenyx Confirms Updated Share Capital and Voting Rights
Neutral
Jan 30, 2026
Hemogenyx Pharmaceuticals has confirmed that its total issued share capital as of 30 January 2026 comprises 6,041,255 ordinary shares of 1p each, with none held in treasury, giving the company an equal number of voting rights. This updated share c...
Delistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
Hemogenyx Sets Early January Date for Admission of New Shares
Neutral
Dec 22, 2025
Hemogenyx Pharmaceuticals has confirmed that the UK Financial Conduct Authority has scheduled an admission hearing for its new ordinary shares on 5 January 2026, with trading in the new shares expected to commence at around 8:00 a.m. on 6 January ...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Hemogenyx Pharmaceuticals Announces Equity Issuance and Operational Updates
Positive
Dec 18, 2025
Hemogenyx Pharmaceuticals plc has issued 123,377 new ordinary shares following warrant exercises, restricted stock unit vesting, and obligations under a Deed of Variation. This issuance, raising £190,000 and leading to adjustments in total is...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.